3SBio Inc
HKEX:1530

Watchlist Manager
3SBio Inc Logo
3SBio Inc
HKEX:1530
Watchlist
Price: 13.06 HKD 9.2% Market Closed
Market Cap: 31.3B HKD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one 3SBio Inc stock under the Base Case scenario is 11.14 HKD. Compared to the current market price of 13.06 HKD, 3SBio Inc is Overvalued by 15%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
11.14 HKD
Overvaluation 15%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.2
P/S
P/S
Price to Sales
3.2
vs History
16
vs Industry
73
Median 3Y
1.9
Median 5Y
2.2
Industry
7
Forward
2.9
More Details
14
P/E
P/E
Price to Earnings
14
vs History
25
vs Industry
9
Median 3Y
8.1
Median 5Y
8.8
Industry
21.5
Forward
12.7
More Details
14.7
P/OCF
P/OCF
Price to OCF
14.7
vs History
0
vs Industry
13
Median 3Y
7.2
Median 5Y
7.9
Industry
20
More Details
75.5
P/FCFE
P/FCFE
Price to FCFE
75.5
vs History
1
vs Industry
3
Median 3Y
10.4
Median 5Y
10.6
Industry
25.4
More Details
2
P/B
P/B
Price to Book Value
2
vs History
3
vs Industry
49
Median 3Y
1
Median 5Y
1.2
Industry
2.4
More Details
2.7
EV/S
EV/S
Enterprise Value to Sales
2.7
vs History
19
vs Industry
67
Median 3Y
1.5
Median 5Y
1.8
Industry
7.3
Forward
2.5
More Details
3.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.1
vs History
20
vs Industry
67
Median 3Y
1.8
Median 5Y
2.2
Industry
9.3
More Details
9.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.1
vs History
16
vs Industry
13
Median 3Y
4.4
Median 5Y
5
Industry
4
Forward
6.7
More Details
10.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.5
vs History
16
vs Industry
11
Median 3Y
5.1
Median 5Y
6
Industry
3.8
Forward
7.9
More Details
12.3
EV/OCF
EV/OCF
Enterprise Value to OCF
12.3
vs History
1
vs Industry
14
Median 3Y
5.4
Median 5Y
6.4
Industry
4.9
More Details
18.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
18.9
vs History
29
vs Industry
9
Median 3Y
9.6
Median 5Y
12.2
Industry
3.3
More Details
1.4
EV/IC
EV/IC
Enterprise Value to IC
1.4
vs History
12
vs Industry
57
Median 3Y
0.7
Median 5Y
0.8
Industry
4.3
More Details

Multiples Across Competitors

Competitors Multiples
3SBio Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
3SBio Inc
HKEX:1530
31.3B HKD 3.2 14 9.1 10.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 662 780 -174 252.8 -211 598.4 -209 183.8
US
Abbvie Inc
NYSE:ABBV
363.9B USD 6.5 86.6 16.8 25.4
US
Amgen Inc
NASDAQ:AMGN
164.3B USD 5 40.5 16.3 28.8
US
Gilead Sciences Inc
NASDAQ:GILD
138B USD 4.8 289 11.3 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.5B USD 11.3 -233.3 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 1 921.5 -490.3 -534 -519.7
AU
CSL Ltd
ASX:CSL
121.8B AUD 5 27.7 17.1 21.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
67.9B USD 4.8 15.4 9.8 10.9
US
Seagen Inc
F:SGT
39.3B EUR 18.5 -56.8 -61 -55.1
NL
argenx SE
XBRU:ARGX
32.3B EUR 16 42 309.2 -2 277.7
P/S Multiple
Revenue Growth P/S to Growth
CN
3SBio Inc
HKEX:1530
Average P/S: 3 333 161.5
3.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
36 662 780
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.3
10%
1.1
US
E
Epizyme Inc
F:EPE
1 921.5
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.8
7%
0.7
US
S
Seagen Inc
F:SGT
18.5
30%
0.6
NL
argenx SE
XBRU:ARGX
16
37%
0.4
P/E Multiple
Earnings Growth PEG
CN
3SBio Inc
HKEX:1530
Average P/E: 73.6
14
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -174 252.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
86.6
87%
1
US
Amgen Inc
NASDAQ:AMGN
40.5
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
289
187%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -233.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -490.3 N/A N/A
AU
CSL Ltd
ASX:CSL
27.7
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
12%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.8 N/A N/A
NL
argenx SE
XBRU:ARGX
42
26%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
3SBio Inc
HKEX:1530
Average EV/EBITDA: 51.9
9.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -211 598.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.8
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.3
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.3
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.8
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -61 N/A N/A
NL
argenx SE
XBRU:ARGX
309.2
166%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
3SBio Inc
HKEX:1530
Average EV/EBIT: 19.7
10.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 183.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.4
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
28.8
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -519.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.4
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.9
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 277.7 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 243,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.